Dhama K, Pawaiya RVS, Chakrabort S, Tiwari R, Saminathan M, Verma AK. Coronavirus infection in equines: a review. Asian J Anim Vet Adv. 2014;9:164–76.
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69.
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:taaa021.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica Atenei Parmensis. 2020;91:157–60.
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20.
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Mol Biol. 2020. https://doi.org/10.1101/2020.01.31.929042.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–9.
Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7:4.
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35–6.
Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microb Infect. 2020;9:221–36.
Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277.
Hui L, Yeming W, Jiuyang X, Bin C. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 2020;43:170–2.
Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8:e11–2.
Xia B, Kang X. Activation and maturation of SARS-CoV main protease. Protein Cell. 2011;2:282–90.
Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55:105950.
Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin N Am. 2010;24:413–37.
Jackman JA, Lee J, Cho N-J. Nanomedicine for infectious disease applications: innovation towards broad-spectrum treatment of viral infections. Small. 2016;12:1133–9.
Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;7:61–4.
Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52:11–8.
Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH, Echeverría J. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol. 2019;10:1207.
Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018;15:93–114.
Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017;4:105–31.
Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20:14051–81.
Choi YH, Han H-K. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018;48:43–60.
Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.
Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360.
Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. J Personal Med. 2017;7:12–20.
Ben-Shabat S, Yarmolinsky L, Porat D, Dahan A. Antiviral effect of phytochemicals from medicinal plants: applications and drug delivery strategies. Drug Deliv Transl Res. 2020;10:354–67.
Gera M, Sharma N, Ghosh M, Huynh DL, Lee SJ, Min T, et al. Nanoformulations of curcumin: an emerging paradigm for improved remedial application. Oncotarget. 2017;8:66680–98.
Praditya D, Kirchhoff L, Brüning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 2019;10:912.
Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine. 2015;10:6055–74.
Mokhtarzadeh A, Eivazzadeh-Keihan R, Pashazadeh P, Hejazi M, Gharaatifar N, Hasanzadeh M, et al. Nanomaterial-based biosensors for detection of pathogenic virus. Trends Anal Chem. 2017;97:445–57.
Kizek R, Krejcova L, Michalek P, Merlos Rodrigo M, Heger Z, Krizkova S, et al. Nanoscale virus biosensors: state of the art. NDD. 2015;4:47–66.
Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019;10:22.
Vijayan V, Mohapatra A, Uthaman S, Park IK. Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics. 2019;11:534.
Luo R, Fang L, Jin H, Wang D, An K, Xu N, et al. Label-free quantitative phosphoproteomic analysis reveals differentially regulated proteins and pathway in PRRSV-Infected Pulmonary Alveolar Macrophages. J Proteome Res. 2014;13:1270–80.
Pan H, Zhang P, Gao D, Zhang Y, Li P, Liu L, et al. Noninvasive visualization of respiratory viral infection using bioorthogonal conjugated near-infrared-emitting quantum dots. ACS Nano. 2014;8:5468–77.
Zhang Y, Ke X, Zheng Z, Zhang C, Zhang Z, Zhang F, et al. Encapsulating quantum dots into enveloped virus in living cells for tracking virus infection. ACS Nano. 2013;7:3896–904.
Kramer A, Assadian O. Survival of microorganisms on inanimate surfaces. In: Use of biocidal surfaces for reduction of healthcare acquired infections. Springer International Publishing AG; 2014. p. 7–26.
Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4:3044–68.
Lee W-S, Hsieh T-C, Shiau JC, Ou T-Y, Chen F-L, Liu Y-H, et al. Bio-Kil, a nano-based disinfectant, reduces environmental bacterial burden and multidrug-resistant organisms in intensive care units. J Microbiol Immunol Infect. 2017;50:737–46.
Karunanayake LI, Waniganayake YC, Gunawardena KDN, Padmaraja SAD, Peter D, Jayasekera R, et al. Use of silicon nanoparticle surface coating in infection control: experience in a tropical healthcare setting. Infect Dis Health. 2019;24:201–7.
Ortí-Lucas RM, Muñoz-Miguel J. Effectiveness of surface coatings containing silver ions in bacterial decontamination in a recovery unit. Antimicrob Resist Infect Control. 2017;6:61.
Si Y, Zhang Z, Wu W, Fu Q, Huang K, Nitin N, et al. Daylight-driven rechargeable antibacterial and antiviral nanofibrous membranes for bioprotective applications. Sci Adv. 2018;4:eaar5931.
Herron JBT, Hay-David AGC, Gilliam AD, Brennan PA. Personal protective equipment and Covid 19—a risk to healthcare staff? Br J Oral Maxillofac Surg. 2020;58(5):500–2.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–7.
Kampf G. Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents. Infect Prev Pract. 2020;2:100044.
Chang A, Schnall AH, Law R, Bronstein AC, Marraffa JM, Spiller HA, et al. Cleaning and disinfectant chemical exposures and temporal associations with COVID-19—National Poison Data System, United States, January 1, 2020–March 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:496–8.
Kapoor A, Saha R. Hand washing agents and surface disinfectants in times of Coronavirus (COVID-19) outbreak. Indian J Community Health. 2020;32:225–7.
Huang H, Fan C, Li M, Nie H-L, Wang F-B, Wang H, et al. COVID-19: a call for physical scientists and engineers. ACS Nano. 2020;14(4):3747–54.
Querido MM, Aguiar L, Neves P, Pereira CC, Teixeira JP. Self-disinfecting surfaces and infection control. Colloids Surf B Biointerfaces. 2019;178:8–21.
Geyer F, D’Acunzi M, Sharifi-Aghili A, Saal A, Gao N, Kaltbeitzel A, et al. When and how self-cleaning of superhydrophobic surfaces works. Sci Adv. 2020;6:eaaw9727.
Dalawai SP, Saad Aly MA, Latthe SS, Xing R, Sutar RS, Nagappan S, et al. Recent advances in durability of superhydrophobic self-cleaning technology: a critical review. Prog Org Coat. 2020;138:105381.
Dyshlyuk L, Babich O, Ivanova S, Vasilchenco N, Prosekov A, Sukhikh S. Suspensions of metal nanoparticles as a basis for protection of internal surfaces of building structures from biodegradation. Case Stud Constr Mater. 2020;12:e00319.
Rai M, Deshmukh SD, Ingle AP, Gupta IR, Galdiero M, Galdiero S. Metal nanoparticles: the protective nanoshield against virus infection. Crit Rev Microbiol. 2016;42:46–56.
Vaze N, Pyrgiotakis G, McDevitt J, Mena L, Melo A, Bedugnis A, et al. Inactivation of common hospital acquired pathogens on surfaces and in air utilizing engineered water nanostructures (EWNS) based nano-sanitizers. Nanomed Nanotechnol Biol Med. 2019;18:234–42.
StatNano. Coronavirus: nanotech surface sanitizes milan with nanomaterials remaining self-sterilized for years | STATNANO. 2020. https://statnano.com//news/67531/Coronavirus-Nanotech-Surface-Sanitizes-Milan-with-Nanomaterials-Remaining-Self-sterilized-for-Years. Accessed 28 Apr 2020.
StatNano. Mineral nanocrystal-based coating activated by light kills coronavirus | STATNANO. 2020. https://statnano.com/news/67583/Mineral-Nanocrystal-based-Coating-Activated-by-Light-Kills-Coronavirus. Accessed 7 Aug 2020.
Chan WCW. Nano research for COVID-19. ACS Nano. 2020;14:3719–20.
Abo-zeid Y, Urbanowicz RA, Thomson BJ, Irving WL, Tarr AW, Garnett MC. Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? Int J Pharm. 2018;547:572–81.
Li Y, Lin Z, Zhao M, Xu T, Wang C, Hua L, et al. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 Influenza Virus through ROS-mediated signaling pathways. ACS Appl Mater Interfaces. 2016;8:24385–93.
Kim J, Yeom M, Lee T, Kim H-O, Na W, Kang A, et al. Porous gold nanoparticles for attenuating infectivity of influenza A virus. J Nanobiotechnol. 2020;18:54.
Sun B, Zhang M, He Z, Zheng L, Shen J, Ni Y. Towards greener and more sustainable cellulose-based hand sanitizer products. JB&B. 2017;2:56–60.
Park S, Ko Y-S, Lee SJ, Lee C, Woo K, Ko G. Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites. Environ Sci Pollut Res. 2018;25:27021–30.
Neal J, Sirsat S. Titanium dioxide nanoparticles as an environmental sanitizing agent. J Microb Biochem Technol. 2015;07:61–4.
Joost U, Juganson K, Visnapuu M, Mortimer M, Kahru A, Nõmmiste E, et al. Photocatalytic antibacterial activity of nano-TiO2 (anatase)-based thin films: effects on Escherichia coli cells and fatty acids. J Photochem Photobiol B. 2015;142:178–85.
Wei G, Nguyen D, Reghu S, Li J, Chua C, Ishida Y, et al. Fast-bactericidal effect of polyion complex nanoparticles on gram-negative bacteria. ACS Appl Nano Mater. 2020;3:2654–64.
Vandhana T, Clement Lourduraj AJ. Biogenic synthesis of Mn-Ag co-doped FeO (Fe1-2xMnxAgx) nanoparticles: as an effective disinfectant and anticancer agent. Inorg Chem Commun. 2020;112:107712.
SZALAY SFD. Skin sanitizer compositions comprising alcohol based emulsion. 2013. https://patents.google.com/patent/EP2654670A2/en. Accessed 26 Apr 2020.
Hu K, Liu H. Preparation method and application of essential oil and plga (poly(lactic-co-glycolic acid)) compounded shell-core structure nanoparticles. CN109568180A. 2019. https://worldwide.espacenet.com/patent/search/family/065924361/publication/CN109568180A?q=CN109568180A&queryLang=en%3Ade%3Afr.
Chiattello ML, Oman M. Polymer-based antimicrobial compositions and methods of use thereof. EP3493676A1. 2019. https://worldwide.espacenet.com/patent/search/family/061011855/publication/EP3493676A1?q=EP3493676A1&queryLang=en%3Ade%3Afr.
Jones S, Stellacci F. Virucidal compounds and uses thereof. EP3487508A1. 2019. https://worldwide.espacenet.com/patent/search/family/056550084/publication/EP3487508A1?q=EP3487508A1&queryLang=en%3Ade%3Afr.
Shivdas HP, Vitthal MR. Environment-friendly silver nanocomposite and method for same. IN1426/MUM/2014, 2015. https://www.quickcompany.in/patents/environment-friendly-silver-nanocomposite-and-method-for-same.
GONDAL MA, Dastageer MA, Khalil AB, Siddique RG, Baig U. Method of forming a photocatalyst and disinfecting a fluid. 2019 https://patents.google.com/patent/US10421672B2/en. Accessed 26 Apr 2020.
Grossman C, Ngo M, Wysocki R. Composition and method to form a self decontaminating surface. 2019. https://patents.google.com/patent/US10421870B2/en. Accessed 26 Apr 2020.
Gutiérrez GL. Nanoparticulate titanium dioxide nanomaterial modified with functional groups and with citric extracts adsorbed on the surface, for the removal of a wide range of microorganisms. 2019. https://patents.google.com/patent/US10342840B2/en. Accessed 19 Apr 2020.
Rösch A, Schaefer C. Metal Dispersion with Increased Stability. EP3368204A1. 2018. https://worldwide.espacenet.com/patent/search/family/057130386/publication/EP3368204A1?q=EP3368204A1&queryLang=en%3Ade%3Afr.
Liu Y, Sun W. Preparation method of nanometer silver/quaternary ammonium salt composite sanitizer. CN108391673A, 2018. https://worldwide.espacenet.com/patent/search/family/063091462/publication/CN108391673A?q=CN108391673A&queryLang=en%3Ade%3Afr.
CDC. Coronavirus disease 2019 (COVID-19)—transmission. Centers for Disease Control and Prevention. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. Accessed 11 Aug 2020.
Conlon M. A facemask having one or more nanofiber layers. 2014. https://patents.google.com/patent/WO2014143039A1/en. Accessed 27 Apr 2020.
Lustenberger F. Nanofiber filtering material for disposable/reusable respirators. 2016. https://patents.google.com/patent/US9446547B2/en. Accessed 27 Apr 2020.
Ren G, Oxford PJS, Reip PW, Lambkin-Williams R, Mann A. Anti-viral formulations nanomaterials and nanoparticles. 2013. https://patents.google.com/patent/US20130091611/de. Accessed 27 Apr 2020.
Yetisen AK, Qu H, Manbachi A, Butt H, Dokmeci MR, Hinestroza JP, et al. Nanotechnology in textiles. ACS Nano. 2016;10:3042–68.
Spagnol C, Fragal EH, Pereira AGB, Nakamura CV, Muniz EC, Follmann HDM, et al. Cellulose nanowhiskers decorated with silver nanoparticles as an additive to antibacterial polymers membranes fabricated by electrospinning. J Colloid Interface Sci. 2018;531:705–15.
Mansi A, Boccuni F, Iavicoli S. Nanomaterials as a new opportunity for protecting workers from biological risk. Ind Health. 2019;57:668–75.
El-Nahhal IM, Salem J, Anbar R, Kodeh FS, Elmanama A. Preparation and antimicrobial activity of ZnO-NPs coated cotton/starch and their functionalized ZnO-Ag/cotton and Zn(II) curcumin/cotton materials. Sci Rep. 2020;10:5410.
Srinivas AD, Peng C, Mittal AC, Agarwal P. Surfaces having particles and related methods. 2014. https://patents.google.com/patent/US20140041905A1/en. Accessed 27 Apr 2020.
Elston DM. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020;82:1085–6.
Kanovsky M. Antimicrobial fabric materials for use in safety masks and personal protection clothing. 2016. https://patents.google.com/patent/WO2016125173A1/no. Accessed 27 Apr 2020.
Clement S. Kupfer(II)enthaltende Formmasse aus Polyester, ihre Herstellung und Verwendung. 2008. https://patents.google.com/patent/DE102007003649A1/de. Accessed 10 Aug 2020.
ФУДЖИMOPИ И, ДЖИКИXИPA И, CATO T, ФУКУИ Й, HAКAЯMA Ц. Virus inactivating cloth. 2015. https://patents.google.com/patent/RU2550922C2/en. Accessed 27 Apr 2020.
Deshmukh SP, Patil SM, Mullani SB, Delekar SD. Silver nanoparticles as an effective disinfectant: a review. Mater Sci Eng C. 2019;97:954–65.
Amigoni S, Josse D, Devers T, Zenerino A, Guittard F, de Givenchy ET, et al. Polymerised cerium oxide nanoparticles in an active or bioactive network, protective topical treatments, methods for preparation thereof and uses thereof. 2018. https://patents.google.com/patent/US10155869B2/en. Accessed 27 Apr 2020.
Ballard RL, Anneaux BL, Manasco JL, Garner DP, Hao P. Electrospun porous media. 2013. https://patents.google.com/patent/US20130197664A1/en. Accessed 27 Apr 2020.
고군호, 박종철. Face mask having nano fiber layer. 2012. https://patents.google.com/patent/KR101130788B1/en. Accessed 23 June 2020.
Kwak JH. Antiviral treatment method, antiviral filter, and mask having same. 2019. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019160261. Accessed 23 June 2020.
Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14:3822–35.
Draz MS, Shafiee H. Applications of gold nanoparticles in virus detection. Theranostics. 2018;8:1985–2017.
Chen L, Liang J. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng C. 2020;112:110924.
Cheng X, Chen G, Rodriguez WR. Micro- and nanotechnology for viral detection. Anal Bioanal Chem. 2009;393:487–501.
Waris A, Ali M, Khan AU, Ali A, Baset A. Exploring pathophysiology of COVID-19 infection: faux espoir and dormant therapeutic options. Int J Clin Virol. 2020;4:065–70.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14:7617–27.
Halfpenny KC, Wright DW. Nanoparticle detection of respiratory infection: nanoparticle detection of respiratory infection. WIREs Nanomed Nanobiotechnol. 2010;2:277–90.
Talebian S, Wallace GG, Schroeder A, Stellacci F, Conde J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat Nanotechnol. 2020;15:618–21.
Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim Acta. 2019;186:224.
Kim H, Park M, Hwang J, Kim JH, Chung D-R, Lee K, et al. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sens. 2019;4:1306–12.
Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25727.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045.
Zhao Z, Cui H, Song W, Ru X, Zhou W, Yu X. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. Mol Biol. 2020. https://doi.org/10.1101/2020.02.22.961268.
Brazilchuck N. From thousands of tiny magnetic balls to 150,000 COVID-19 tests per week. Norwegian SciTech News. 2020. https://norwegianscitechnews.com/2020/04/from-thousands-of-tiny-magnetic-balls-to-150000-covid-19-tests-per-week/. Accessed 10 Aug 2020.
Seo G, Lee G, Kim MJ, Baek S-H, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in Human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14:5135–42.
Santiago I. Trends and innovations in biosensors for COVID-19 mass testing. ChemBioChem. 2020. https://doi.org/10.1002/cbic.202000250.
Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. 2020;30:189–90.
Solaimuthu A, Vijayan AN, Murali P, Korrapati PS. Nano-biosensors and their relevance in tissue engineering. Curr Opin Biomed Eng. 2020;13:84–93.
Zhu X, Wang X, Han L, Chen T, Wang L, Li H, et al. Reverse transcription loop-mediated isothermal amplification combined with nanoparticles-based biosensor for diagnosis of COVID-19. 2020. https://doi.org/10.1101/2020.03.17.20037796.
Chen Z, Zhang Z, Zhai X, Li Y, Lin L, Zhao H, et al. Rapid and Sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal Chem. 2020;92:7226–31.
Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. ACS Nano. 2020;14:5268–77.
Somvanshi SB, Kharat PB, Saraf TS, Somwanshi SB, Shejul SB, Jadhav KM. Multifunctional nano-magnetic particles assisted viral RNA-extraction protocol for potential detection of COVID-19. Mater Res Innov. 2020;24:1–6.
Wang M, Fu A, Hu B, Tong Y, Liu R, Liu Z, et al. Nanopore targeted sequencing for the accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. Small. 2020;16(32):2002169.
Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C, et al. One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. BioRxiv. 2020;142373:1–18.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–36.
Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267.
García-Serradilla M, Risco C, Pacheco B. Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res. 2019;264:22–31.
Teissier E, Penin F, Pécheur E-I. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules. 2010;16:221–50.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295:4773–9.
Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjørås M, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020;93:268–76.
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:1–5.
Clercq ED, Li G. approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695–747.
Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–21.
Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012;23:1–12.
Sofias AM, Andreassen T, Hak S. Nanoparticle ligand-decoration procedures affect in vivo interactions with immune cells. Mol Pharm. 2018;15:5754–61.
Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–13.
Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005–10.
Testori A. The “perfect cytokine storm” of covID-19. Mayo Clin Proc. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256537/.
Khalvati B, Sheikhsaran F, Sharifzadeh S, Kalantari T, Behzad Behbahani A, Jamshidzadeh A, et al. Delivery of plasmid encoding interleukin-12 gene into hepatocytes by conjugated polyethylenimine-based nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:1036–44.
Zeng L, Ma W, Shi L, Chen X, Wu R, Zhang Y, et al. Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy. IJN. 2019;14:6357–69.
Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm. 2014;11:1042–52.
Duncan SA, Dixit S, Sahu R, Martin D, Baganizi DR, Nyairo E, et al. Prolonged release and functionality of interleukin-10 encapsulated within PLA-PEG nanoparticles. Nanomaterials. 2019;9:1074.
Dormont F, Brusini R, Cailleau C, Reynaud F, Peramo A, Gendron A, et al. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. Sci Adv. 2020;6:eaaz5466.
Loutfy SA, Elberry MH, Farroh KY, Mohamed HT, Mohamed AA, Mohamed EB, et al. Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. IJN. 2020;15:2699–715.
Dey P, Bergmann T, Cuellar-Camacho JL, Ehrmann S, Chowdhury MS, Zhang M, et al. Multivalent flexible nanogels exhibit broad-spectrum antiviral activity by blocking virus entry. ACS Nano. 2018;12:6429–42.
Hendricks GL, Weirich KL, Viswanathan K, Li J, Shriver ZH, Ashour J, et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus. J Biol Chem. 2013;288:8061–73.
Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen Y-T, et al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl Mater Interfaces. 2019;11:42964–74.
Hu C-MJ, Chen Y-T, Fang Z-S, Chang W-S, Chen H-W. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection. Int J Nanomed. 2018;13:8579–93.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(865–876):e12.
Baram-Pinto D, Shukla S, Gedanken A, Sarid R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small. 2010;6:1044–50.
Liu L, Chopra P, Li X, Wolfert MA, Tompkins SM, Boons G-J. SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner. BioRxiv. 2020. https://doi.org/10.1101/2020.05.10.087288.
Cagno V, Andreozzi P, D’Alicarnasso M, Jacob Silva P, Mueller M, Galloux M, et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018;17:195–203.
Jones ST, Cagno V, Janeček M, Ortiz D, Gasilova N, Piret J, et al. Modified cyclodextrins as broad-spectrum antivirals. Sci Adv. 2020;6:eaax9318.
Wu C-J, Huang H-W, Liu C-Y, Hong C-F, Chan Y-L. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 2005;65:45–8.
Li T, Zhang Y, Fu L, Yu C, Li X, Li Y, et al. siRNA targeting the Leader sequence of SARS-CoV inhibits virus replication. Gene Ther. 2005;12:751–61.
Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28:174–84.
Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur Rev Med Pharmacol Sci. 2020;24:2781–3.
Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for COVID-19. EXCLI J. 2020;19:528–31.
Levanova A, Poranen MM. RNA interference as a prospective tool for the control of human viral infections. Front Microbiol. 2018;9:2151.
Rohiwal SS, Dvorakova N, Klima J, Vaskovicova M, Senigl F, Slouf M, et al. Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing. Sci Rep. 2020;10:4619.
Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–36.
Tanaka P, Santos J, Oliveira E, Miglioli N, Assis A, Monteleone-Cassiano A, et al. A Crispr-Cas9 system designed to introduce point mutations into the human ACE2 gene to weaken the interaction of the ACE2 receptor with the SARS-CoV-2 S protein. Preprints; 2020. https://www.preprints.org/manuscript/202005.0134/v1. Accessed 19 June 2020.
Deng H, Huang W, Zhang Z. Nanotechnology based CRISPR/Cas9 system delivery for genome editing: progress and prospect. Nano Res. 2019;12:2437–50.
Aghamiri S, Talaei S, Ghavidel AA, Zandsalimi F, Masoumi S, Hafshejani NH, et al. Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in cancer treatment. J Drug Deliv Sci Technol. 2020;56:101533.
Glass Z, Li Y, Xu Q. Nanoparticles for CRISPR–Cas9 delivery. Nat Biomed Eng. 2017;1:854–5.
Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1:889–901.
Chen F, Alphonse M, Liu Q. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. WIREs Nanomed Nanobiotechnol. 2020;12:e1609.
Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater. 2019;31:1902575.
Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Investig. 2016;126:799.
Sautto GA, Kirchenbaum GA, Diotti RA, Criscuolo E, Ferrara F. Next generation vaccines for infectious diseases. J Immunol Res. 2019;2019:5890962.
Lung P, Yang J, Li Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020;12:5746–63.
Kim S-H, Jang Y-S. The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin Exp Vaccine Res. 2017;6:15.
Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines. 2019;7:37.
Kim CG, Kye Y-C, Yun C-H. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8+ T cell responses. Pharmaceutics. 2019;11:612.
Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006;40:1–9.
Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15:646–55.
Espeseth AS, Cejas PJ, Citron MP, Wang D, DiStefano DJ, Callahan C, et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. npj Vaccines. 2020;5:16.
Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE. 2012;7:e31472.
Papadopoulos NG, Megremis S, Kitsioulis NA, Vangelatou O, West P, Xepapadaki P. Promising approaches for the treatment and prevention of viral respiratory illnesses. J Allergy Clin Immunol. 2017;140:921–32.
Gomes AC, Mohsen M, Bachmann MF. Harnessing nanoparticles for immunomodulation and vaccines. Vaccines. 2017;5:6.
Angioletti-Uberti S. Theory, simulations and the design of functionalized nanoparticles for biomedical applications: a soft matter perspective. npj Comput Mater. 2017;3:48.
Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv. 2017;3:e1601556.
Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 Vaccines At Pandemic Speed. N Engl J Med. 2020;382:1969–73.
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–9.
Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–36.
Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. BioRxiv. 2020. https://doi.org/10.1101/2020.03.20.000141.
EpiVax. EPV-CoV19: HCW vaccine. EpiVax, Inc.—Informatics and Immunology. 2020. https://epivax.com/pipeline/epv-cov19. Accessed 16 June 2020.
Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224–33.
Novavax. Novavax to receive up to $388 million funding from CEPI for COVID-19 vaccine development and manufacturing | Novavax Inc. - IR Site. 2020. http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine. Accessed 16 June 2020.
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79.
WHO. Draft landscape of COVID-19 candidate vaccines. 2020. https://www.who.int/who-documents-detail-redirect/draft-landscape-of-covid-19-candidate-vaccines. Accessed 13 June 2020.
Sportelli MC, Picca RA, Cioffi N. Recent advances in the synthesis and characterization of nano-antimicrobials. Trends Anal Chem. 2016;84:131–8.
Gunell M, Haapanen J, Brobbey KJ, Saarinen JJ, Toivakka M, Mäkelä JM, et al. Antimicrobial characterization of silver nanoparticle-coated surfaces by “touch test” method. Nanotechnol Sci Appl. 2017;10:137–45.
Swaminathan M, Sharma NK. Antimicrobial Activity of the engineered nanoparticles used as coating agents. In: Martínez LMT, Kharissova OV, Kharisov BI, editors. Handbook of ecomaterials. Cham: Springer International Publishing; 2019. p. 549–63. https://doi.org/10.1007/978-3-319-68255-6_1. Accessed 28 Apr 2020.
Mitchell SL, Carlson EE. Tiny things with enormous impact: nanotechnology in the fight against infectious disease. ACS Infect Dis. 2018;4:1432–5.
Polyak B, Cordovez B. How can we predict behavior of nanoparticles in vivo ? Nanomedicine. 2016;11:189–92.
Beyth N, Houri-Haddad Y, Domb A, Khan W, Hazan R. Alternative antimicrobial approach: nano-antimicrobial materials. Hindawi. 2015;1:246012.
Wacker MG, Proykova A, Santos GML. Dealing with nanosafety around the globe-regulation vs. innovation. Int J Pharm. 2016;509:95–106.
Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther. 2017;42:742–55.
Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9:e1416.
Zhdanov VP. Formation of a protein corona around nanoparticles. Curr Opin Colloid Interface Sci. 2019;41:95–103.
Lane LA, Qian X, Smith AM, Nie S. Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem. 2015;66:521–47.
Berrecoso G, Crecente-Campo J, Alonso MJ. Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers. Drug Deliv Transl Res. 2020;10:730–50.